In a report released today, Matt Hewitt from Craig-Hallum reiterated a Buy rating on BioLife Solutions (BLFS – Research Report). The company’s shares closed last Wednesday at $27.69.
According to TipRanks, Hewitt is a 3-star analyst with an average return of 2.7% and a 48.91% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Lifecore Biomedical, Inotiv, and Simulations Plus.
BioLife Solutions has an analyst consensus of Strong Buy, with a price target consensus of $30.78, an 11.16% upside from current levels. In a report released on January 8, Northland Securities also maintained a Buy rating on the stock with a $31.00 price target.
BLFS market cap is currently $1.28B and has a P/E ratio of -33.88.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
BioLife Solutions (BLFS) Company Description:
BioLife Solutions, Inc. engages in the development, manufacture, and marketing of biopreservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1998 and it is headquartered in Bothell, WA.
Read More on BLFS:
- BioLife Solutions price target raised to $31 from $28 at Northland
- BioLife Solutions Strengthens Board with Tony J. Hunt Appointment
- Azenta upgraded to Overweight, named new ‘Best Idea’ at Stephens
- BioLife Solutions appoints Hunt to board of directors
- BioLife Solutions price target raised to $33 from $30 at KeyBanc
